Charles Grassley

Latest Headlines

Latest Headlines

The U.S. taxman may come for pharma's foreign profits

Caution: Big Pharma's tax-avoidance tactics are in jeopardy. As Bloomberg reports, U.S. lawmakers are eyeing overseas profits--and the $7 billion-plus in taxes sidestepped by drugmakers last year--with changes in mind.

Groups lobby White House as sunshine rule lingers

The rule for how drug and device makers will have to disclose their financial ties to doctors is 15 months overdue and the longer White House officials sit on it, the more lobbying it gets from different sides trying to shape its final wording.

EU OKs Vertex cystic fibrosis drug Kalydeco

About 6 months after the FDA gave the nod to Vertex Pharmaceuticals' pricey drug Kalydeco, the European Commission also approved the treatment for patients with cystic fibrosis that have a certain genetic mutation.

Senator castigates FDA for spying on scientists' email

Sen. Charles Grassey, a longtime FDA critic, isn't pulling any punches now that the agency spying on employees has been detailed in the press.

Senator blasts FDA for spying on internal whistleblowers

In a blistering letter to the FDA, Sen. Charles E. Grassley said that the electronic surveillance of the scientists inside the agency was approved by its attorneys in writing. And he's not in the least bit happy to see headlines about secret probes aimed at the agency's internal critics.

Senate probes ties among narcoticsmakers, pain organizations

The Senate Finance Committee launched an investigation yesterday into the ties among companies that sell pain drugs, pain experts, patient advocacy groups and professional organizations, The New York Times reports.

NYT: Psych text ghostwritten by pharma

Two doctors who've previously drawn scrutiny for failing to disclose financial ties to the drug industry are now under fire for publishing a treatment text that may have been ghostwritten by

GAO joins FDA in congressional spotlight

The FDA's Office of Criminal Investigation is now joined in the congressional spotlight by the Government Accountability Office, which had been sent to investigate it. The case provides a rare

Should FDA split safety ops from CDER?

There's been a move afoot for some time to separate the FDA's drug-safety operations from the Center for Drug Evaluation and Research, which now oversees both drug approvals and safety. The thinking

Grassley's key pharma investigator jumps ship

Drugmakers could well be rejoicing at the news that Paul Thacker, an investigator for Sen. Chuck Grassley (R-Iowa) who led some high-profile pharma probes, is leaving to join a non-profit group.